Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies

2017 ◽  
Vol 36 (2) ◽  
pp. 189-204 ◽  
Author(s):  
Sergio Iannazzo ◽  
Ange-Christelle Iliza ◽  
Louise Perrault
Keyword(s):  
Multiple Sclerosis ◽  
Cost Effectiveness ◽  
Literature Review ◽  
Systematic Literature Review ◽  
Disease Modifying Therapies ◽  
Disease Modifying ◽  
Effectiveness Studies

scholarly journals Active Pulmonary Tuberculosis Triggered by Interferon Beta-1b Therapy of Multiple Sclerosis: Four Case Reports and a Literature Review

Medicina ◽  
2020 ◽  
Vol 56 (4) ◽  
pp. 202 ◽  
Author(s):  
Carmen Adella Sirbu ◽  
Elena Dantes ◽  
Cristina Florentina Plesa ◽  
Any Docu Axelerad ◽  
Minerva Claudia Ghinescu
Keyword(s):  
Multiple Sclerosis ◽  
Mycobacterium Tuberculosis ◽  
Literature Review ◽  
Interferon Beta ◽  
Latent Infection ◽  
Case Reports ◽  
Active Tuberculosis ◽  
Active Pulmonary Tuberculosis ◽  
Disease Modifying Therapies ◽  
Disease Modifying

In this paper, we reported on four cases of severe pulmonary active tuberculosis in patients with multiple sclerosis (MS) undergoing interferon beta-1b (IFNβ-1b) therapy. Disease-modifying therapies (DMTs) in MS may increase the risk of developing active tuberculosis (TB) due to their impact on cellular immunity. Screening for latent infection with Mycobacterium tuberculosis (LTBI) should be performed, not only for the newer DMTs (alemtuzumab, ocrelizumab) but also for IFNβ-1b, alongside better supervision of these patients.

Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain

2013 ◽  
Vol 15 (4) ◽  
pp. 353-362 ◽  
Author(s):  
Carole Dembek ◽  
Leigh Ann White ◽  
Jayson Quach ◽  
Andrea Szkurhan ◽  
Nazia Rashid ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cost Effectiveness ◽  
Disease Modifying Therapies ◽  
Disease Modifying

Reporting treatment outcomes in observational data: A fine balance

2016 ◽  
Vol 23 (1) ◽  
pp. 21-22 ◽  
Author(s):  
Tomas Kalincik ◽  
Maria Pia Sormani
Keyword(s):  
Multiple Sclerosis ◽  
Cost Effectiveness ◽  
High Risk ◽  
Treatment Outcomes ◽  
Observational Data ◽  
Risk Of Bias ◽  
Statistical Methodology ◽  
Disease Modifying Therapies ◽  
Disease Modifying

Analyses of observational data have been gaining momentum in the evaluation of ever increasing spectrum of disease modifying therapies for multiple sclerosis. While high cost-effectiveness and generalisability represent their main advantages, these studies are also burdened with high risk of bias that may lead to erroneous conclusions. In this viewpoint, we highlight the key role of rigorous and transparent statistical methodology in the studies of observational data and encourage its thorough editorial scrutiny.

Sign in / Sign up

Export Citation Format

Share Document